To the extent that MAFLD may be the same as NAFLD, for which Hsp90β had been pinpointed (see above), here too, a careful classification of MAFLD/NAFLD patients with respect to clinical parameters and Hsp90 levels will be necessary before any Hsp90-based therapy can be considered. The gene discussed is HSP90AA1; the disease is metabolic dysfunction-associated steatotic liver disease.